The relationship between MnSOD Val16Ala gene polymorphism and the level of serum total antioxidant capacity with the risk of chronic kidney disease in type 2 diabetic patients: a nested case-control study in the Tehran lipid glucose study

• DOI: 10.1186/s12986-018-0264-0
• Publication Date: 2018-04-11T13:14:11Z
• Authors: Mehrnaz Abbasi; Maryam S. Daneshpour; Mehdi Hedayati; Azadeh Mottaghi; Katayoun Pourvali; Fereidoun Azizi
• Keywords: Val16Ala polymorphism; 0303 health sciences; RC620-627; Nutrition. Foods and food supply; Val16Ala polymorphism ; Type 2 diabetes mellitus ; Total antioxidant capacity (TAC) ; Chronic kidney disease ; Manganese mitochondrial superoxide dismutase (MnSOD); Manganese mitochondrial superoxide dismutase (MnSOD); Research; Total antioxidant capacity (TAC); 3. Good health; 03 medical and health sciences; Chronic kidney disease; Type 2 diabetes mellitus; TX341-641; Nutritional diseases. Deficiency diseases

Several studies have shown significant associations between manganese superoxide dismutase (MnSOD) Val16Ala polymorphism and diabetic complications, but this association has not been explored in relation with chronic kidney disease (CKD) in Type 2 diabetes mellitus (T2DM) patients. Total antioxidant capacity (TAC) level changes in diabetic condition and may play important role in onset or progression of the disease and its complications. The present study investigated the association of MnSOD Val16Ala polymorphism and serum TAC with the risk of CKD in T2DM patients.This nested case-control study included 280 type 2 diabetic patients with CKD and 280 age, sex and diabetes duration-matched control subjects selected from the participants of the Tehran Lipid and Glucose Study. MnSOD val16Ala (rs4880) SNP was genotyped by the Tetra-Primer ARMS-polymerase chain reaction analysis. Serum TAC was measured using ferric-reducing antioxidant power assay. Statistical analysis was performed using STATA statistical package v.12.0 or SPSS (Version 22.0).The Ala allele of the MnSOD Val16Ala polymorphism was associated with a lower risk of CKD (odds ratio (OR), 0.55; 95% confidence interval (CI), 0.36-0.84; P = 0.006). Median serum TAC in CKD group was 920 μmol/L and was significantly lower (p < 0.001) compared to the control group (1045 μmol/L). Using an adjusted conditional logistic regression, we didn't observe any significant interaction between MnSOD Val16Ala SNP with quartiles of serum TAC in relation to CKD.A significant association was found between the MnSOD Val16Ala polymorphism and CKD, but this association is not affected by serum TAC level in T2DM patients.